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Abstract:  The  ability  to  escape  apoptosis  or  programmed  cell  death  is  a  hallmark  of 
human cancers, for example pancreatic cancer. This can promote tumorigenesis, since too 
little cell death by apoptosis disturbs tissue homeostasis. Additionally, defective apoptosis 
signaling is the underlying cause of failure to respond to current treatment approaches, 
since therapy-mediated antitumor activity requires the intactness of apoptosis signaling 
pathways in cancer cells. Thus, the elucidation of defects in the regulation of apoptosis in 
pancreatic  carcinoma  can  result  in  the  identification  of  novel  targets  for  therapeutic 
interference and for exploitation for cancer drug discovery. 
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1. Introduction  
Tissue homeostasis critically depends on a subtle balance between cell growth and cell death and is 
typically disturbed in human cancers [1].This implies that a reduced rate of programmed cell death 
(apoptosis) and/or an increase in cell proliferation can lead to tumor formation [1]. Apoptosis is a 
highly conserved form of cell death that already occurs in lower organisms [2]. Apoptosis exerts vital 
functions in many physiological processes and is found to be deregulated in a large variety of human 
diseases [1]. For example, a hallmark of human cancers including pancreatic carcinoma is the inability 
of  cells  to  undergo  apoptosis  in  response  to  an  apoptotic  stimulus  [3,4].  Deregulated  apoptosis 
programs are often also the underlying cause of primary or acquired resistance of pancreatic carcinoma 
to  current  therapies,  including  chemo-,  radio-  or  immunotherapy,  since  these  treatment  strategies 
primarily act by triggering the intrinsic cell death program in target cancer cells [5]. The elucidation of 
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apoptosis pathways and their deregulation in pancreatic cancer therefore harbors a great potential for 
the  development  of  novel  experimental  cancer  therapeutics  that  are  targeted  to  the  underlying 
molecular mechanisms of treatment resistance. Such an approach is expected to have the ability to 
bypass classical drug resistance mechanisms.  
2. Pancreatic Cancer 
Pancreatic cancer represents currently one of the leading causes of cancer deaths in the Western 
world with a very poor prognosis despite intensive protocols [6,7]. This poor outcome is, at least in 
part, due to the resistance of pancreatic cancer to the currently available treatment options and still 
constitutes one of the most challenging problems in oncology [8]. Evasion of apoptosis substantially 
contributes  to  this  treatment  failure,  since  cytotoxic  cancer  therapies  depend  on  the  induction  of 
apoptosis in cancer cells in order to be effective [5]. Thus, strategies that target defective apoptosis 
programs may open new perspectives to improve the prognosis of pancreatic cancer patients.  
3. Apoptosis Signaling Pathways  
A  large  variety  of  stimuli  that  originate  both  from  the  exterior  of  the  cell,  for  example  death 
receptors, chemotherapeutic agents or therapeutic antibodies, or alternatively from the inside of a cell, 
such  as  reactive  oxygen  species  or  metabolic  end  products,  can  initiate  apoptosis  [1].  In  case  of 
caspase-dependent apoptosis, the activation of apoptosis signaling pathways results in the activation of 
caspases [9]. Caspases are a family of cysteine proteases that act as death effector molecules in many 
forms of cell death [9]. Caspases are synthesized as inactive proenzymes and cleavage or dimerization 
is required for their activation [9]. 
Caspases  can  become  activated  by  two  principal  pathways,  i.e.,  the  death  receptor  (extrinsic) 
pathway  and  the  mitochondrial  (intrinsic)  pathway  [10].  In  the  death  receptor  pathway,  the 
engagement of death receptors by their corresponding ligands, for example agonistic TRAIL receptors, 
leads to the activation of the initiator caspase-8 [11]. Once activated caspase-8 either directly cleaves 
effector caspases such as caspase-3 or, alternatively, initiates the mitochondrial pathway by cleaving 
Bid. The processed form of Bid, i.e., tBid, in turn translocates to mitochondrial membranes, where it 
initiates the release of mitochondrial intermembrane space proteins such as cytochrome c into the 
cytosol [12,13]. In the cytosol, cytochrome c forms a multimeric complex together with Apaf-1 and 
caspase-9 termed the apoptosome complex, which is responsible for caspase-3 activation [13]. 
It is important to note that there are also additional forms of cell death beyond apoptosis [14]. These 
non-apoptotic  cell  death  modes  include  e.g.  necrosis,  autophagy,  lysosomal  cell  death  or  mitotic 
catastrophe [14]. There is mounting evidence that the type of cell death is highly dependent on the 
cellular context and that different forms of cell death may occur in parallel in a given system.  
4. Targeting Apoptosis for the Treatment of Pancreatic Cancer  
4.1. Death Receptor Signaling as Therapeutic Target in Pancreatic Cancer  
Death  receptors  are  part  of  the  tumor  necrosis  factor  (TNF)  receptor  gene  superfamily  
of  transmembrane  receptors  that  are  characterized  by  an  intracellular  domain  called  the  Cancers 2011, 3                                       
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“death domain” [11]. This domain transmits the death signal from the surface of a cell to intracellular 
signaling pathways and serves as a platform for the recruitment of signaling molecules that transmit 
the death signal such as the adaptor protein FADD and caspase-8 [11]. Binding of death receptor 
ligands  such  as  TRAIL  to  their  corresponding  receptors  leads  to  the  recruitment  of  FADD  and  
caspase-8 to the activated death receptor. This results in the formation of the death-inducing signaling 
complex (DISC) at the plasma membrane, i.e., which in turn leads to caspase-8 activation [11]. 
The concept is to target death receptors for cancer therapy, since death receptors can directly engage 
the  cell  death  program  of  cancer  cells.  To  this  end,  TRAIL  presents  the  most  promising  clinical 
candidate,  since  it  preferentially  triggers  apoptosis  in  cancer  over  non-malignant  cells  [11].  The 
presence  of  TRAIL  receptors  exposed  on  the  surface  of  cell  membranes  offers  the  possibility  of 
inducing apoptosis in cancer cells by the exogenous administration of compounds capable of directly 
engaging two agonistic TRAIL receptors, i.e., TRAIL-R1 and TRAIL-R2 [11]. By comparison, two 
antagonistic decoy receptors, TRAIL-R3 and TRAIL-R4, bind TRAIL, but do not signal cell death, 
and  osteoprotegerin  acts  as  a  soluble  decoy  receptor  [11].  At  least  one  of  the  agonistic  TRAIL 
receptors has been reported to be expressed in human pancreatic carcinoma tissue, while conflicting 
reports have been made on expression of TRAIL decoy receptors [15-18]. Although the majority of 
pancreatic carcinoma cell lines were found to express the essential signaling molecules of the TRAIL 
pathway [19-21], most of them turned out to be refractory to TRAIL [21,22]. However, sensitivity 
towards  TRAIL could be  restored by various combination therapies, e.g.  using chemotherapeutics 
(camptothecin, cisplatin, celecoxib) that downregulate c-FLIP expression [23]. Also in a xenografts 
mouse  model  of  pancreatic  adenocarcinoma,  TRAIL  together  with  gemcitabine  showed  a  greater  
anti-tumor effect than either monotherapy used alone [24]. Along this line, anti-TRAIL receptor 2 
antibody  combined  with  CPT-11  caused  inhibition  of  tumor  growth  in  an  orthotopic  model  of 
pancreatic  cancer  [25].  Also,  pharmacologic  or  genetic  inhibition  of  CDK4  enhanced  the  TRAIL 
sensitivity  [26].  Moreover,  the  estradiol  metabolite  2-Methoxyestradiol  promoted  TRAIL-induced 
apoptosis by upregulating TRAIL receptors via generation of oxidative stress and JNK activation [27]. 
Combination therapy with the proteasome inhibitor bortezomib similarly enhanced TRAIL-induced 
apoptosis  via  upregulation  of  TRAIL-R1/TRAIL-R2,  downregulation  of  c-FLIPL  and  increase  in  
Bak [28]. These various combination strategies indicate that the antitumor activity of TRAIL can 
substantially be augmented by the addition of other cytotoxic principles. 
Expression levels of O-glycosyltransferases may serve as biomarkers to predict TRAIL sensitivity, 
as they are overexpressed in several cancers and regulate TRAIL-induced apoptosis via modulation of 
TRAIL-R1 or -R2 [29]. 
Various  agents  have  been  developed  in  recent  years  to  target  the  TRAIL  system  for  clinical 
application [30]. For example, soluble TRAIL and agonistic antibodies directed against the TRAIL 
receptors TRAIL-R1 and -R2 were developed [31,32]. In pancreatic carcinoma, Apomab (agonistic 
antibody against TRAIL-R2) was shown to be effective in pancreatic cancer as a single agent and in 
combination with chemotherapy [33]. At present, TRAIL-R1 monoclonal antibodies are being tested in 
early clinical trials alone or in combination with chemotherapeutic drugs [34]. 
In addition to the induction of apoptosis, TRAIL may also exert non-apoptotic functions, including 
activation  of  survival  cascades  such  as  NF-κB,  PI3K/Akt  or  Ras/Raf/ERK  pathways  [35].  For 
example, TRAIL was shown to enhance metastasis formation in an orthotopic mouse model of human Cancers 2011, 3                                       
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pancreatic carcinoma [36]. Thus, clinical protocols with TRAIL have to take also those activities into 
consideration. 
4.2. “Inhibitor of Apoptosis” (IAP) Proteins as Therapeutic Targets in Pancreatic Cancer 
“Inhibitor of Apoptosis” (IAP) proteins comprise a family of endogenous caspase inhibitors with 
eight human analogues, i.e., XIAP, cIAP1, cIAP2, survivin, livin (ML-IAP), NAIP, Bruce (apollon) 
and ILP-2 [37]. All IAP proteins harbor at least one baculovirus IAP repeat (BIR) domain, which 
presents the interaction domain with caspases. Among the IAP family proteins, XIAP has shown the 
most potent anti-apoptotic effects by inhibiting active caspase-3 and -7 and by preventing caspase-9 
activation [37,38]. The IAP family protein survivin not only regulates apoptosis, but also controls 
mitotic events [39]. IAP proteins are negatively controlled at several levels, e.g. by mitochondrial 
(Smac/DIABLO) or nuclear proteins (i.e., XIAP-associated factor 1 (XAF-1)) [37]. IAP proteins are 
also targets of caspase-mediated cleavage as well as ubiquitination-mediated proteasomal degradation 
via auto- and heteroubiquitination through the RING domain of IAP proteins [37]. 
In pancreatic cancer, high expression levels of several of the IAP proteins have been reported in 
comparison  to  non-malignant  pancreatic  ductal  cells  or  pancreatic  tissue,  including  XIAP,  cIAP2, 
survivin  and  livin  [40-43].  In  addition,  low  expression  levels  of  XAF1  were  recently  shown  to 
correlate  with  shorter  survival  times  in  pancreatic  cancer  [44].  In  multivariate  analysis,  XAF1 
expression turned out as an independent prognostic indicator of the survival of these patients [44]. 
In order to target the expression and/or function of IAP proteins in pancreatic cancer, a number of 
approaches were developed. So far, most of these strategies are directed against XIAP, since XIAP 
possesses the most potent anti-apoptotic properties among the IAP proteins [38], for example, RNA 
interference (RNAi) or antisense oligonucleotides. To this end, RNAi-mediated downregulation of 
XIAP was reported to increase apoptosis of pancreatic carcinoma cells following treatment with death 
receptor ligands, such as TRAIL or agonistic anti-CD95 antibodies, as well as after γ-irradiation and 
also  suppressed  colony  formation  [21,45].  Additionally,  the  combination  of  XIAP  inhibition  and 
TRAIL even overcame Bcl-2-conferred resistance [46]. This involved a switch of type II cells, which 
require the mitochondrial contribution to TRAIL-induced apoptosis, to type I cells in which TRAIL 
triggers apoptosis irrespective of Bcl-2 overexpression [46]. Also, inhibition of XIAP cooperated with 
TRAIL  to  trigger  regression  of  established  pancreatic  carcinoma  in  a  tumor  regression  model  in 
xenograft-bearing mice [46]. Similarly, loss of XIAP protein upon administration of XIAP antisense 
oligonucleotides  increased  TRAIL-mediated  apoptosis  in  a  pancreatic  carcinoma  cell  line  [47]. 
Downregulation  of  XIAP  or  cIAP2  also  increased  the  response  to  anticancer  drugs  including 
doxorubicin, paclitaxel, gemcitabine and cisplatin, at least in some pancreatic cancer cell lines [41,42]. 
Loss  of  XIAP  protein  upon  administration  of  XIAP  antisense  oligonucleotides  correlated  with 
increased sensitization to TRAIL-mediated apoptosis in a pancreatic carcinoma cell line [47]. XIAP 
antisense oligonucleotides against XIAP are currently under evaluation in early clinical trials [48].  
The binding groove of the BIR3 domain of XIAP, which binds Smac, has served as a target for the 
design of compounds that inhibit XIAP [49]. In pancreatic cancer, Smac peptides were reported to 
sensitize pancreatic cancer cells to both death-receptor- or anticancer drug-induced apoptosis [50]. To 
facilitate  intracellular  delivery,  a  carrier  was  coupled  to  Smac  peptides,  for  example  the  protein Cancers 2011, 3                                       
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transduction motif of the HIV Tat protein [50]. Smac mimetics were also found in another study to 
potentiate the chemotherapy response [51]. In addition, small molecule XIAP inhibitors synergized 
with TRAIL to induce apoptosis both in vitro and in vivo, causing regression of pancreatic carcinoma [43]. 
Also, XIAP inhibitors potentiated radiosensitivity of pancreatic carcinoma cells by enhancing caspase 
cleavage and subsequently apoptosis in response to γ-irradiation [45]. 
In addition to synthetic small molecule inhibitors, Embelin, a natural compound from the Japanese 
Ardisia herb, was identified as a XIAP inhibitor [52]. In pancreatic carcinoma cell lines, Embelin 
enhanced TRAIL-induced apoptosis [53]. 
Besides the BIR2 domain of XIAP, small molecule compounds were also designed against the BIR2 
domain of the protein. To this end, the screening of a polyphenylurea library resulted in the identification 
of several non-peptidic compounds with potent binding to the BIR2 domain of XIAP [54,55]. In pancreatic 
carcinoma  cells,  these  polyphenylurea  compounds  induced  apoptosis  as  single  agents  and  also 
increased the induction of apoptosis following treatment with gemcitabine, TRAIL or irradiation [40]. 
4.3. Mitochondria as Therapeutic Target in Pancreatic Cancer 
The Bcl-2 family of proteins comprises both anti-apoptotic members, e.g. Bcl-2, Bcl-XL, Mcl-1, and 
pro-apoptotic proteins including Bax, Bak, Bad and BH3 domain only-proteins [12]. Imbalances in the 
ratio of anti-apoptotic versus pro-apoptotic Bcl-2 proteins with a relative increase in the anti-apoptotic 
molecules  have  been  reported  for  several  human  cancers.  How  BH3-only  proteins  initiate  the 
activation of Bax and Bak has still not exactly been identified and there are currently two alternative 
working models. In the direct activation model [56], BH3-only proteins that act as direct activators, 
i.e., Bim and cleaved Bid (tBid), bind to Bax and Bak to trigger their activation, while BH3-only 
proteins that act as sensitizers, e.g. Bad, bind to the pro-survival Bcl-2 proteins. According to the 
indirect  activation  model,  BH3-only  proteins  activate  Bax  and  Bak  indirectly  by  engaging  
anti-apoptotic Bcl-2 proteins, thereby freeing up Bax and Bak [57,58]. Furthermore, Bak activation 
requires inactivation of both, Bcl-XL and Mcl-1 [59].  
Various  strategies  have  been  developed  over  the  last  years  to  antagonize  anti-apoptotic  Bcl-2-
related  proteins  in  human  cancers.  For  example,  targeting  of  the  protein-protein  interaction  site 
between anti-apoptotic Bcl-2 proteins and the multimeric pro-apoptotic Bcl-2 proteins Bax or Bak 
yielded small molecule antagonists that bind to the surface groove of Bcl-2, Bcl-XL and Bcl-w in a 
similar manner as the BH3 domain of Bax or Bak [60]. ABT-737 represents the prototypic compound 
of this class of inhibitors that has been extensively characterized in preclinical models [61]. ABT-737 
was shown to directly trigger apoptosis in susceptible cell lines, e.g. chronic lymphocytic leukemia 
cells, or to sensitize cancer cells for apoptosis [60]. Recently, ABT-737 and TRAIL were found to 
synergize in the induction of cell death in pancreatic cancer cells by stimulating the intrinsic and 
extrinsic apoptotic pathways, respectively [62]. Obatoclax, another BH3 mimetic, antagonizes Bcl-2, 
Bcl-XL, Bcl-w as well as Mcl-1 [63]. In pancreatic cancer Obatoclax has shown to potentiate TRAIL-
triggered apoptosis [64]. ABT-263, an oral analogue with improved pharmacokinetic properties, is 
currently  evaluated  in  early  clinical  trials  in  small-cell  lung  cancer  and  B-cell  malignancies  [65].  
TW-37 presents another small-molecule inhibitor of Bcl-2, which was shown to inhibit cell growth and 
invasion and increased apoptosis in pancreatic cancer [66]. Another approach to target anti-apoptotic Cancers 2011, 3                                       
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Bcl-2 proteins is the use of antisense oligonucleotides. For example, Bcl-XL antisense oligonucleotides 
enhanced gemcitabine- or irradiation-induced cytotoxicity in pancreatic cancer cells [67,68].  
5. Conclusions 
Pancreatic  cancer  harbors  multiple  defects  in  apoptosis  signaling  pathways  that  contribute  to 
tumorigenesis and favors treatment resistance, including high levels of anti-apoptotic proteins and/or 
reduced expression or function of pro-apoptotic proteins. Several components of apoptosis signaling 
pathways  may  be  exploited  as  targets  for  the  development  of  experimental  cancer  therapies,  for 
example  the  TRAIL  system,  IAP  proteins  or  anti-apoptotic  Bcl-2  proteins.  The  transfer  of  this 
knowledge  on  apoptosis  signaling  into  the  design  of  experimental  clinical  trials  may  offer  novel 
perspectives to improve the prognosis of pancreatic cancer patients. 
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